Craft

Mesoblast

Stock Price

$1.5

2024-10-04

Market Capitalization

$1.7 B

2024-10-04

Revenue

$5.9 M

FY, 2024

Mesoblast Summary

Company Summary

Overview
Mesoblast specializes in the development of biologic products for the broad field of regenerative medicine. It offers a diverse portfolio of cell-based product candidates with three programs in Phase 3 clinical studies. The Company's patented Mesenchymal Precursor Cell (MPC) technology is being developed for an extensive range of major clinical diseases, including inflammatory and immunologic conditions of the joints and lungs, diabetes and kidney disease, orthopedic spine conditions, and cardiovascular disorders.
Type
Public
Status
Active
Founded
2004
HQ
Melbourne, AU | view all locations
Website
https://www.mesoblast.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Silviu Itescu
  • Joseph R Swedish

    Joseph R Swedish, Chair Of The Board Of Directors

  • Shawn Cline Tomasello

    Shawn Cline Tomasello, Non-Executive Director

    • Andrew Chaponnel

      Andrew Chaponnel, Interim Chief Financial Officer

    LocationsView all

    3 locations detected

    • Melbourne, VIC HQ

      Australia

      Level 38/55 Collins St

    • New York, NY

      United States

      505 5th Ave Level 3

    • Singapore

      Singapore

      21 Biopolis Rd

    Mesoblast Financials

    Summary Financials

    Revenue (H1, 2025)
    $3.2M
    Gross profit (H1, 2025)
    $17.9M
    Net income (H1, 2025)
    ($47.9M)
    Cash (H1, 2025)
    $38.0M
    EBIT (H1, 2025)
    ($36.2M)
    Enterprise value
    $1.8B

    Footer menu